JAN 2019

Antibiotics Market - Growth, Trends, and Forecast (2019 - 2024)

The Antibiotics Market is segmented by Type, Spectrum (Broad Spectrum Antibody and Narrow Spectrum Antibody), and Geography

Market Snapshot

antibiotics market-1
Study Period:

2019-2024

Base year:

2018

Fastest growing market:

Asia Pacific

Largest market:

North America

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Summary

The global antibiotics market was valued at USD 42,653.89 million in 2018, and is estimated to be valued at USD 56,369.92 million in 2024, witnessing a CAGR of 4.7%. Certain factors that are driving the market growth include the emergence of anti-MRSA drugs, development of generic drugs, and vulnerable aging population.

A company that initially produced the patented drug tries to generate maximum revenue before the patent expires. Once the patent expires, there will be many competitors who begin manufacturing the generic formulations. They have the same composition and same pharmacological activities as of the original drug. Almost 80% of the prescription antibiotics are generic. As a result of this, the price is reduced. More people can afford drugs, thus, resulting in improved healthcare outcomes. However, indiscriminate drug usage also leads to drug resistance and other complications.

Scope of the Report

As per the scope of the report, antibiotic medicines are among the most prescribed courses worldwide, in fighting bacterial infections, primarily in outpatient settings.

By Product Type
Cephalosporins
Penicillins
Fluroquinilones
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
Other Product Types
By Spectrum
Broad-spectrum Antibiotics
Narrow-spectrum Antibiotics
Geography
North America
United States
Canada
Mexico
Europe
France
Germany
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Carbapenems are Expected to Show the Rapid Growth of in the Future.

The cephalosporin segment is expected to account for the largest market size during the forecast period. Carbapenems are expected to witness the highest CAGR of around 5.9% during the forecast period.

The rising threat of drug resistance and a weak pipeline of new molecules are leading to the development of combinational formulations. For instance, in countries, like India, the emergence of multi-drug-resistant tuberculosis (TB) is a major factor driving the R&D expenditures. Methicillin-resistant Staphylococcus aureus (MRSA) is another bacterium responsible for several infections in humans that are difficult to treat. The MRSA infection is difficult to treat with standard antibiotics, such as penicillins (methicillin, dicloxacillin, nafcillin, and oxacillin), and the cephalosporins. In 2014, the US Food and Drug Administration (FDA) approved four new antibiotics for the treatment of infections caused by gram-positive bacteria, including MRSA.

Antibiotics-2

To understand key trends, Download Sample Report

North America is Expected to Dominate the Market in the Forcasted Period

North America currently dominates the market for antibiotics and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of antibiotics. The United States holds the majority of the market in the North American region, due to the fact that the United States has the highest antibiotic prescribing rate in the North American region. In addition, there is a rise in per capita health expenditure in the country, which is expected to increase over the forecast period, owing to decrease in the unemployment rate.

antibiotics market-3

To understand geography trends, Download Sample Report

Competitive Landscape

The antibiotics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products with less prices. Companies, like Glaxosmithkline, Pfizer PLC, Bayer AG, Novartis AG, and Abbott Inc., hold significant market shares in the antibiotics market.

Major Players

  1. GlaxoSmithKline PLC
  2. Johnson & Johnson Inc.
  3. Merck & Co. Inc.
  4. Pfizer Inc.
  5. Bayer AG

* Complete list of players covered available in the table of contents below

Antibiotics-4

Download the market shares of key players in this industry.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Emergence of Anti-MRSA/VRE Drugs

      2. 4.2.2 Development of Generic Drugs

      3. 4.2.3 Vulnerable Aging Population

    3. 4.3 Market Restraints

      1. 4.3.1 Antibiotic Resistance

      2. 4.3.2 Fewer Companies Involved in Active Research

      3. 4.3.3 Time Taken for Regulatory Approval

    4. 4.4 Industry Attractiveness – Porter’s Five Forces Analysis

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Cephalosporins

      2. 5.1.2 Penicillins

      3. 5.1.3 Fluroquinilones

      4. 5.1.4 Macrolides

      5. 5.1.5 Carbapenems

      6. 5.1.6 Aminoglycosides

      7. 5.1.7 Sulfonamides

      8. 5.1.8 Other Product Types

    2. 5.2 By Spectrum

      1. 5.2.1 Broad-spectrum Antibiotics

      2. 5.2.2 Narrow-spectrum Antibiotics

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 France

        2. 5.3.2.2 Germany

        3. 5.3.2.3 United Kingdom

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 GlaxoSmithKline PLC

      2. 6.1.2 Johnson & Johnson Inc.

      3. 6.1.3 Merck & Co. Inc.

      4. 6.1.4 Pfizer Inc.

      5. 6.1.5 Bayer Healthcare AG

      6. 6.1.6 Novartis AG

      7. 6.1.7 Sanofi SA

      8. 6.1.8 Abbott Laboratories

      9. 6.1.9 Roche Holding AG

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information